Impact BioLife

Impact BioLife Science is a Nevada-incorporated healthcare and biotechnology company that operates as a wholly owned subsidiary of Impact BioMedical. The entity appears to function as one of the intellectual-property and operating subsidiaries within the broader Impact BioMedical group, which is developing a portfolio spanning biopharmaceutical, antiviral, antimicrobial, metabolic health, and consumer wellness technologies. Public materials associate the group’s core programs with the Linebacker, Laetose, Equivir, and 3F platforms, targeting areas such as inflammatory disease, oncology, neurology, antiviral products, and metabolic health. Impact BioLife Science is also named as the assignee or filer on at least some patent assets, including antimicrobial plastic intellectual property. There is no evidence that Impact BioLife Science itself is separately public; instead, it appears to be held under the publicly traded parent Impact BioMedical.